Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study

Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study

PurposeApatinib is an approved third-line treatment for metastatic gastric cancer in China and demonstrates good safety, tolerability, and efficacy in other advanced solid tumors. The aim of this prospective, single-arm, multicenter, phase 2 study was to assess the efficacy and safety of low-dose ap...

Full description

Bibliographic Details
Main Authors: Ning Li, Wenying Deng, Guifang Zhang, Yali Du, Yanwei Guo, Yijie Ma, Chen Wei, Liangyu Bie, Chi Zhang, Tao Song, Suxia Luo, Baijun Fang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
apatinib
S-1
colorectal cancer
metastatic
efficacy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.728854/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.728854/full

Similar Items